Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131

OBJECTIVE: To evaluate the positive predictive value of detectable Tg during T4 therapy (Tg on T4) in patients with thyroid cancer after total thyroidectomy and remnant ablation, discussing the work-up in this situation and the empirical indication of 131I. PATIENTS AND METHODS: Initially, 234 low-risk patients [tumor < 5cm, completely resected, no extensive extrathyroid invasion (pT4)] submitted to total thyroidectomy and ablation with 131I (3.7­5.5 GBq) who presented no ectopic uptake on RxWBS were studied. Of these, 23 patients with detectable Tg on T4 (> 1ng/ml) during the first year after initial therapy were selected. RESULTS: Metastases were detected by neck US in 7 patients, by chest CT in 2 and by US and CT in 3. Four of five patients with lung metastases upon CT had a positive RxWBS. Eleven patients with negative US and CT received a new 131I dose (without DxWBS), and RxWBS showed ectopic uptake in 3 patients. Among the patients with negative RxWBS, 7 remained free of apparent disease and Tg was declining (5 with undetectable Tg on T4 at the end of the study). One patient presented an increase in Tg and FDG-PET was positive for lymph node and bone metastases. CONCLUSIONS: All patients with Tg on T4 > 5ng/ml presented apparent disease. In these cases, even when US and CT are negative, the administration of a therapeutic dose of 131I (without DxWBS) and FDG-PET are recommended. Among patients with detectable Tg on T4 < 5ng/ml and negative US and CT, only 12% presented ectopic uptake on RxWBS. These cases could be followed up by monitoring Tg on T4, and RxWBS and FDG-PET should only be performed if this marker does not decrease after 1­2 years.

Saved in:
Bibliographic Details
Main Authors: Rosário,Pedro W.S., Borges,Michelle A.R., Costa,Graciela B.C., Rezende,Leonardo L., Padrão,Eduardo L., Barroso,Álvaro L., Purisch,Saulo
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Endocrinologia e Metabologia 2007
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302007000100016
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-27302007000100016
record_format ojs
spelling oai:scielo:S0004-273020070001000162007-04-12Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131Rosário,Pedro W.S.Borges,Michelle A.R.Costa,Graciela B.C.Rezende,Leonardo L.Padrão,Eduardo L.Barroso,Álvaro L.Purisch,Saulo Detectable Tg on T4 Radioiodine Thyroid cancer OBJECTIVE: To evaluate the positive predictive value of detectable Tg during T4 therapy (Tg on T4) in patients with thyroid cancer after total thyroidectomy and remnant ablation, discussing the work-up in this situation and the empirical indication of 131I. PATIENTS AND METHODS: Initially, 234 low-risk patients [tumor < 5cm, completely resected, no extensive extrathyroid invasion (pT4)] submitted to total thyroidectomy and ablation with 131I (3.7­5.5 GBq) who presented no ectopic uptake on RxWBS were studied. Of these, 23 patients with detectable Tg on T4 (> 1ng/ml) during the first year after initial therapy were selected. RESULTS: Metastases were detected by neck US in 7 patients, by chest CT in 2 and by US and CT in 3. Four of five patients with lung metastases upon CT had a positive RxWBS. Eleven patients with negative US and CT received a new 131I dose (without DxWBS), and RxWBS showed ectopic uptake in 3 patients. Among the patients with negative RxWBS, 7 remained free of apparent disease and Tg was declining (5 with undetectable Tg on T4 at the end of the study). One patient presented an increase in Tg and FDG-PET was positive for lymph node and bone metastases. CONCLUSIONS: All patients with Tg on T4 > 5ng/ml presented apparent disease. In these cases, even when US and CT are negative, the administration of a therapeutic dose of 131I (without DxWBS) and FDG-PET are recommended. Among patients with detectable Tg on T4 < 5ng/ml and negative US and CT, only 12% presented ectopic uptake on RxWBS. These cases could be followed up by monitoring Tg on T4, and RxWBS and FDG-PET should only be performed if this marker does not decrease after 1­2 years.info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArquivos Brasileiros de Endocrinologia &amp; Metabologia v.51 n.1 20072007-02-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302007000100016en10.1590/S0004-27302007000100016
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Rosário,Pedro W.S.
Borges,Michelle A.R.
Costa,Graciela B.C.
Rezende,Leonardo L.
Padrão,Eduardo L.
Barroso,Álvaro L.
Purisch,Saulo
spellingShingle Rosário,Pedro W.S.
Borges,Michelle A.R.
Costa,Graciela B.C.
Rezende,Leonardo L.
Padrão,Eduardo L.
Barroso,Álvaro L.
Purisch,Saulo
Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131
author_facet Rosário,Pedro W.S.
Borges,Michelle A.R.
Costa,Graciela B.C.
Rezende,Leonardo L.
Padrão,Eduardo L.
Barroso,Álvaro L.
Purisch,Saulo
author_sort Rosário,Pedro W.S.
title Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131
title_short Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131
title_full Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131
title_fullStr Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131
title_full_unstemmed Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131
title_sort management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on t4 after thyroidectomy and ablation with iodine-131
description OBJECTIVE: To evaluate the positive predictive value of detectable Tg during T4 therapy (Tg on T4) in patients with thyroid cancer after total thyroidectomy and remnant ablation, discussing the work-up in this situation and the empirical indication of 131I. PATIENTS AND METHODS: Initially, 234 low-risk patients [tumor < 5cm, completely resected, no extensive extrathyroid invasion (pT4)] submitted to total thyroidectomy and ablation with 131I (3.7­5.5 GBq) who presented no ectopic uptake on RxWBS were studied. Of these, 23 patients with detectable Tg on T4 (> 1ng/ml) during the first year after initial therapy were selected. RESULTS: Metastases were detected by neck US in 7 patients, by chest CT in 2 and by US and CT in 3. Four of five patients with lung metastases upon CT had a positive RxWBS. Eleven patients with negative US and CT received a new 131I dose (without DxWBS), and RxWBS showed ectopic uptake in 3 patients. Among the patients with negative RxWBS, 7 remained free of apparent disease and Tg was declining (5 with undetectable Tg on T4 at the end of the study). One patient presented an increase in Tg and FDG-PET was positive for lymph node and bone metastases. CONCLUSIONS: All patients with Tg on T4 > 5ng/ml presented apparent disease. In these cases, even when US and CT are negative, the administration of a therapeutic dose of 131I (without DxWBS) and FDG-PET are recommended. Among patients with detectable Tg on T4 < 5ng/ml and negative US and CT, only 12% presented ectopic uptake on RxWBS. These cases could be followed up by monitoring Tg on T4, and RxWBS and FDG-PET should only be performed if this marker does not decrease after 1­2 years.
publisher Sociedade Brasileira de Endocrinologia e Metabologia
publishDate 2007
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302007000100016
work_keys_str_mv AT rosariopedrows managementoflowriskpatientswiththyroidcarcinomaanddetectablethyroglobulinont4afterthyroidectomyandablationwithiodine131
AT borgesmichellear managementoflowriskpatientswiththyroidcarcinomaanddetectablethyroglobulinont4afterthyroidectomyandablationwithiodine131
AT costagracielabc managementoflowriskpatientswiththyroidcarcinomaanddetectablethyroglobulinont4afterthyroidectomyandablationwithiodine131
AT rezendeleonardol managementoflowriskpatientswiththyroidcarcinomaanddetectablethyroglobulinont4afterthyroidectomyandablationwithiodine131
AT padraoeduardol managementoflowriskpatientswiththyroidcarcinomaanddetectablethyroglobulinont4afterthyroidectomyandablationwithiodine131
AT barrosoalvarol managementoflowriskpatientswiththyroidcarcinomaanddetectablethyroglobulinont4afterthyroidectomyandablationwithiodine131
AT purischsaulo managementoflowriskpatientswiththyroidcarcinomaanddetectablethyroglobulinont4afterthyroidectomyandablationwithiodine131
_version_ 1756372613726208000